Blog Empty Image

Which of the following vaccines is required to be stored in a freezer?
 
a. Hepatitis A
b. Human papilloma virus
c. Influenza
d. Herpes Zoster


Which of the following vaccines is required to be stored in a freezer?
 
a. Hepatitis A
b. Human papilloma virus
c. Influenza
d. Herpes Zoster

Answer: Herpes zoster.

The following vaccines are required to be stored in refrigerator (2 to 8 degree C):

1. HepA (Hepatitis A)
2. HepB (Hepatitis B)
3. Hib (Haemophilus influenzae type b)
4. HPV (Human papilloma virus)
5. Influenza
6. Meningococcal-combinations
7. Pneumococcal
8. Rotavirus
9. Any diphtheria/tetanus toxoid, pertussis combination
 
The following vaccines are required to be stored in freezer (-50 to -15 degrees C):

1. VAR (Varicella)
2. HZV (Herpes Zoster Vaccine)
3. MMRV = Measles, mumps, rubella, varicella
 
The following vaccines can be stored in refrigerator (2 to 8 degree C) or freezer (-50 to -15 degrees C):

1. MMR (Measles, mumps, rubella)


Clobazam is classified as a:
 
a. Schedule II controlled drug
b. Schedule III controlled drug
c. Schedule IV controlled drug
d. Schedule V controlled drug
 


Clobazam is classified as a:
 
a. Schedule II controlled drug
b. Schedule III controlled drug
c. Schedule IV controlled drug
d. Schedule V controlled drug
 
Answer: (c). The active ingredient found in Onfi is Clobazam. It is classified as schedule IV controlled substance. Each Onfi (Clobazam) tablet contains 10 mg or 20 mg of clobazam. It is also available for oral administration as an off-white suspension containing clobazam at a concentration of 2.5 mg/mL.
 
Onfi (Clobazam) is classified as benzodiazepine. Clobazam potentiates the GABAergic neurotransmission by binding at the benzodiazepine site of the GABAa receptor.
 
Onfi (Clobazam) is indicated for the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients 2 years of age or older.
 
A daily dose of Onfi (Clobazam) greater than 5 mg should be administered in divided doses twice daily; a 5 mg daily dose can be administered as a single dose.
 
As with all antiepileptic drugs and benzodiazepines, withdraw Onfi (Clobazam) gradually. The patient should taper by decreasing the total daily dose by 5-10 mg/day on a weekly basis until discontinued.
 
Somnolence, depression, sedation, withdrawal symptoms, serious dermatological reactions and suicidal behavior and ideation are commonly reported side effects of Onfi (Clobazam).
 
www.pharmacyexam.com


Blog Empty Image

Coming at a time when heroin and opioid overdoses are gripping the nation, a new Colorado law allows pharmacies to sell naloxone without a prescription. A number of states are allowing measures like Colorado’s to combat increasing overdose death rates associated with prescription opioid and heroin abuse.
 
NABP’s AWARXE® Prescription Drug Safety Program is working to reduce opioid and heroin overdose deaths by educating the public on prescription drug abuse and misuse. The program’s website offers resources such as facts on the dangers of prescription drug abuse, informational flyers and posters, and a Locator Tool to help consumers find prescription drug disposal programs near them.


Coming at a time when heroin and opioid overdoses are gripping the nation, a new Colorado law allows pharmacies to sell naloxone without a prescription. A number of states are allowing measures like Colorado’s to combat increasing overdose death rates associated with prescription opioid and heroin abuse.
 
NABP’s AWARXE® Prescription Drug Safety Program is working to reduce opioid and heroin overdose deaths by educating the public on prescription drug abuse and misuse. The program’s website offers resources such as facts on the dangers of prescription drug abuse, informational flyers and posters, and a Locator Tool to help consumers find prescription drug disposal programs near them.


Blog Empty Image

Which of the following drugs utilizes ZipDose Technology?

a. Olanzapine
b. Metoprolol
c. Levetiracetam
d. Fluoxetine
e. Amoxicillin


Which of the following drugs utilizes ZipDose Technology?

a. Olanzapine
b. Metoprolol
c. Levetiracetam
d. Fluoxetine
e. Amoxicillin

Answer: Levetiracetam. Levetiracetam (Spritam) is indicated for the treatment of partial onset seizures, myoclonic seizures and primary generalized tonic-clonic seizures in adults and children with epilepsy.
 
Spritam utilizes Aprecia's proprietary ZipDose® Technology platform, a groundbreaking advance that uses three-dimensional printing (3DP) to produce a porous formulation that rapidly disintegrates with a sip of liquid.1 While 3DP has been used previously to manufacture medical devices, this approval marks the first time a drug product manufactured with this technology has been approved by the FDA.
 
ZipDose Technology enables the delivery of a high drug load, up to 1,000 mg in a single dose. As a result, Spritam enhances the patient experience - administration of even the largest strengths of Levetiracetam (Spritam) with just a sip of liquid. In addition, with Spritam there is no measuring required as each dose is individually packaged, making it easy to carry this treatment on the go.
 
The recommended daily dose is 1000 to 3000 mg per day.
 
Sleepiness, weakness, dizziness, infection, tiredness, acting aggressive, nasal congestion, decreased appetite, and irritability are commonly reported side effects of Levetiracetam (Spritam).
 
Levetiracetam is also available under the trade names Keppra and Elepsia.


Blog Empty Image

New Jersey Governor Chris Christie recently signed into law a bill that will require prescribers and pharmacists to register for the state’s prescription monitoring program (PMP) and to check the database that tracks controlled substance (CS) prescriptions under certain situations. The legislation, S-1998, includes the following requirements:
 
Pharmacists will be required to consult the state PMP before dispensing a Schedule II CS if they believe the patient may be seeking the prescription for any use other than medical treatment.

Pharmacists will be required to report dispensing a CS no more than seven days after doing so.

On September 1, 2015, pharmacists will be required to report CS prescription information daily, or no more than one business day after a CS was dispensed. Pharmacists must also submit identifying information for anyone who picks up a controlled substance prescription on behalf of another patient if abuse or misuse is suspected.

Under the law, prescribers must consult the PMP the first time they prescribe a Schedule II CS to a patient for acute and chronic pain, and quarterly thereafter for patients who continue to receive such medications. More information about the new law is available in a press release from the governor’s office.
 
Source: www.nabp.net


New Jersey Governor Chris Christie recently signed into law a bill that will require prescribers and pharmacists to register for the state’s prescription monitoring program (PMP) and to check the database that tracks controlled substance (CS) prescriptions under certain situations. The legislation, S-1998, includes the following requirements:
 
Pharmacists will be required to consult the state PMP before dispensing a Schedule II CS if they believe the patient may be seeking the prescription for any use other than medical treatment.
Pharmacists will be required to report dispensing a CS no more than seven days after doing so.

On September 1, 2015, pharmacists will be required to report CS prescription information daily, or no more than one business day after a CS was dispensed. Pharmacists must also submit identifying information for anyone who picks up a controlled substance prescription on behalf of another patient if abuse or misuse is suspected.

Under the law, prescribers must consult the PMP the first time they prescribe a Schedule II CS to a patient for acute and chronic pain, and quarterly thereafter for patients who continue to receive such medications. More information about the new law is available in a press release from the governor’s office.
 
Source: www.nabp.net


Blog Empty Image

Ohio pharmacists are among the latest in the country to be allowed to dispense naloxone, a drug that reverses opioid overdose, without a prescription. Last week, Ohio Governor John Kasich signed into law modifications to Section 4729.44 of the Ohio Revised Code and Rule 4729-5-39 of the Ohio Administrative Code allowing pharmacists to dispense the drug under a physician-approved protocol. The legislation is effective immediately, and the Ohio State Board of Pharmacy has compiled information and other resources on its website to help pharmacists comply with the new rules.


Ohio pharmacists are among the latest in the country to be allowed to dispense naloxone, a drug that reverses opioid overdose, without a prescription. Last week, Ohio Governor John Kasich signed into law modifications to Section 4729.44 of the Ohio Revised Code and Rule 4729-5-39 of the Ohio Administrative Code allowing pharmacists to dispense the drug under a physician-approved protocol. The legislation is effective immediately, and the Ohio State Board of Pharmacy has compiled information and other resources on its website to help pharmacists comply with the new rules.

Source:http://www.nabp.net/news/ohio-pharmacists-can-now-dispense-naloxone-without-a-prescription


Blog Empty Image

Levetiracetam is indicated for the treatment of:

a. Diabetes
b. Hypertension
c. Seizure
d. Parkinson’s
e. Depression



Levetiracetam is indicated for the treatment of:

a. Diabetes
b. Hypertension
c. Seizure
d. Parkinson’s
e. Depression

Answer: Seizure. Levetiracetam (Spritam) is indicated for the treatment of partial onset seizures, myoclonic seizures and primary generalized tonic-clonic seizures in adults and children with epilepsy.
 
Spritam utilizes Aprecia's proprietary ZipDose® Technology platform, a groundbreaking advance that uses three-dimensional printing (3DP) to produce a porous formulation that rapidly disintegrates with a sip of liquid.1 While 3DP has been used previously to manufacture medical devices, this approval marks the first time a drug product manufactured with this technology has been approved by the FDA.
 
ZipDose Technology enables the delivery of a high drug load, up to 1,000 mg in a single dose. As a result, Spritam enhances the patient experience - administration of even the largest strengths of Levetiracetam (Spritam) with just a sip of liquid. In addition, with Spritam there is no measuring required as each dose is individually packaged, making it easy to carry this treatment on the go.
 
The recommended daily dose is 1000 to 3000 mg per day.
 
Sleepiness, weakness, dizziness, infection, tiredness, acting aggressive, nasal congestion, decreased appetite, and irritability are commonly reported side effects of Levetiracetam (Spritam).
 
Levetiracetam is also available under the trade names Keppra and Elepsia.




Free USA Shipping! No Minimum Order.
Free International Shipping! Over $200 or More.